ECOG Performance Status Calculator — Oncology Eligibility & KPS Conversion

How to Use This Calculator

1. Select the ECOG description that best matches the patient's current functional level.
2. ECOG score, KPS equivalent, and clinical notes display instantly.
3. Use the Categories tab for full descriptor text and clinical examples.
4. Use the KPS Conversion tab to translate between scales.

Formula

Example

Frequently Asked Questions

• What is ECOG Performance Status? ▼
  ECOG Performance Status (PS) is a standardised six-point scale used in oncology to quantify a patient's level of functioning in terms of their ability to perform activities of daily living and work. It was developed by the Eastern Cooperative Oncology Group (ECOG) and first published by Oken et al. in the American Journal of Clinical Oncology in 1982. The scale runs from 0 (fully active, no restriction) to 5 (dead). ECOG 0 denotes a patient who functions normally in all respects. ECOG 1 indicates restriction in physically strenuous activity but the patient can still perform light or sedentary work. ECOG 2 means the patient is ambulatory and self-caring but cannot perform any work activities, and is up more than 50% of waking hours. ECOG 3 indicates the patient is confined to bed or chair for more than 50% of waking hours and capable of only limited self-care. ECOG 4 is completely disabled — the patient cannot care for themselves at all. ECOG 5 is dead. The scale was designed to be quickly and reproducibly assessed by any clinician in under one minute, making it practical for routine oncology care and research.
• Why is ECOG widely used in oncology? ▼
  ECOG Performance Status became the dominant functional assessment scale in oncology for several interconnected reasons. Its simplicity — just six levels assessed with a single question — means it can be evaluated in seconds during a clinical encounter without specialised equipment or training. Its strong prognostic validity has been confirmed in hundreds of clinical trials across virtually all cancer types; ECOG PS is one of the most consistently significant prognostic factors for overall survival and treatment tolerance in multivariate analyses. Its widespread adoption by cooperative oncology groups (ECOG, SWOG, CALGB) in the 1980s and 1990s created a common language across trials, enabling cross-study comparison of patient populations. Regulatory bodies and drug developers adopted it as a standard eligibility criterion, creating further institutional inertia. ECOG 0-1 eligibility criteria in clinical trials serve two functions: ensuring enrolled patients can tolerate experimental treatments (safety) and ensuring a relatively homogeneous patient population (scientific validity). Despite its limitations — modest inter-rater reliability (kappa approximately 0.4), failure to capture cognitive function or symptom burden, and susceptibility to observer bias — no replacement scale has achieved comparable adoption.
• What ECOG score is required for clinical trials? ▼
  Most phase II and phase III oncology clinical trials require ECOG Performance Status of 0 or 1 as an eligibility criterion. This threshold ensures that enrolled patients are ambulatory, functionally capable, and likely to tolerate treatment-related toxicities. Trials of particularly toxic regimens (high-dose chemotherapy, bispecific antibodies in haematological malignancies) may restrict enrolment to ECOG 0 only. Some trials — particularly those studying less toxic agents like oral targeted therapies, immunotherapy, or agents specifically designed for more vulnerable populations — include patients with ECOG 2 performance status. Phase I dose-escalation trials, whose primary objective is safety assessment rather than efficacy, typically require ECOG ≤2. There is an important asymmetry: patients with ECOG 2 from cancer-related functional impairment may respond dramatically to effective targeted therapy and rapidly improve their performance status (e.g., an EGFR-mutant lung cancer patient with ECOG 2 who receives osimertinib). This "treatability" dimension is not captured by the numerical score. ECOG scores should therefore be interpreted in the context of whether the impairment is reversible.
• Can ECOG status change during treatment? ▼
  ECOG Performance Status is not static and can change significantly during the course of oncology treatment. Effective therapy that produces tumour regression, reduction in pain, or improvement in cancer-related fatigue frequently improves ECOG status — sometimes by one or two levels within weeks of starting effective systemic therapy. Conversely, disease progression, treatment toxicity, or intercurrent illness can worsen performance status. This dynamic nature has important clinical implications. ECOG should be re-assessed at each clinic visit, particularly before each cycle of chemotherapy or targeted therapy. A patient who was ECOG 0 at baseline may decline to ECOG 2 after several cycles of toxic chemotherapy; this should prompt dose modification, growth factor support, or treatment interruption. Serial ECOG assessments also have prognostic value — patients whose PS deteriorates despite treatment have significantly worse outcomes than those whose PS remains stable or improves. The trajectory of ECOG change is at least as informative as the absolute value at a single time point. In clinical trials, ECOG is typically assessed at screening, at the start of each treatment cycle, and at disease assessment visits.
• How do you convert ECOG score to Karnofsky Performance Status? ▼
  The approximate conversion between ECOG and KPS is well established in the literature. ECOG 0 corresponds to KPS 90–100 (normal activity, no symptoms to minor symptoms). ECOG 1 corresponds to KPS 70–80 (normal activity with effort; some symptoms). ECOG 2 corresponds to KPS 50–70 (self-care but no work; ambulatory). ECOG 3 corresponds to KPS 30–50 (limited self-care; more than half of time in bed). ECOG 4 corresponds to KPS 10–30 (disabled to moribund). ECOG 5 is KPS 0 (dead). These conversions are approximate because the two scales have different granularities — KPS offers 10-step increments across a 0–100 range while ECOG has just six levels. The KPS boundaries at each ECOG level overlap considerably. In direct comparison studies, the correlation between ECOG and KPS is strong (Pearson r approximately 0.7–0.8), but individual patient-level disagreement between raters using the two scales is common. ECOG is preferred for clinical trial enrolment criteria and most North American/European oncology guidelines. KPS remains dominant in palliative care and hospice settings, where finer discrimination at the lower end of function — captured by KPS 10, 20, 30, and 40 — has practical value for prognosis and care intensity decisions.

Related Calculators